Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?

K. C. Chang, C. C. Leung, W. W. Yew, T. Y. Lau, W. M. Leung, C. M. Tam, H. C. Lam, P. S. Tse, M. Y. Wong, S. N. Lee, K. I. Wat, Y. H. Ma
European Respiratory Journal 2010 35: 606-613; DOI: 10.1183/09031936.00104209
K. C. Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. C. Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. W. Yew
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Y. Lau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. M. Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. M. Tam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. C. Lam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. S. Tse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Y. Wong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. N. Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. I. Wat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. H. Ma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Possible masking of tuberculosis (TB) in treatment of community-acquired respiratory infection by newer fluoroquinolones has not been examined in randomised controlled trials.

We undertook a randomised, open-label controlled trial involving adults with community-acquired pneumonia or infective exacerbation of bronchiectasis encountered in government chest clinics in Hong Kong. 427 participants were assigned by random permutated blocks of 20 to receive either amoxicillin clavulanate (n = 212) or moxifloxacin (n = 215). Participants were followed for 1 yr for active pulmonary TB.

Excluding three participants with positive baseline culture, 13 developed active pulmonary TB: 10 (4.8%) out of 210 were given amoxicillin clavulanate, and three (1.4%) out of 214 were given moxifloxacin. The difference was significant by both proportion and time-to-event analysis. Post hoc analysis showed a significant decrease in the proportion with active pulmonary TB from 4.8% to 2.4% and 0% among participants given amoxicillin clavulanate (n = 210), moxifloxacin for predominantly 5 days (n = 127) and 10 days (n = 87), respectively. The log rank test for trend also showed a significant difference between the three subgroups. Regression models reaffirmed the linear effect; the adjusted odds ratio (95% confidence interval) of active pulmonary TB after moxifloxacin exposure up to predominantly 10 days was 0.3 (0.1–0.9).

Newer fluoroquinolones appear to mask active pulmonary TB.

  • Fluoroquinolones
  • tuberculosis

With broad-spectrum antimicrobial coverage including β-lactamase-producing bacteria, penicillin-resistant Streptococcus pneumoniae, and pathogens causing atypical pneumonia, newer fluoroquinolones have demonstrated effectiveness in treatment of community-acquired respiratory infection 1–6. The Infectious Diseases Society of America and the American Thoracic Society have recommended newer fluoroquinolones for treating community-acquired pneumonia (CAP) in the presence of comorbidities or risk factors for drug-resistant S. pneumoniae infection 7. Like older fluoroquinolones, which have demonstrated an important role in treatment of multidrug-resistant tuberculosis (TB) 8–11, newer fluoroquinolones have shown prominent anti-TB activity in the initial phase of TB treatment with potential for shortening treatment duration 12, 13.

Possible masking of active TB in the treatment of CAP by fluoroquinolones has been suggested by retrospective analysis 14, but not been verified by randomised controlled trials in TB-endemic areas. Hong Kong is endemic for TB with annual notification rates at ∼80 per 100,000 persons 15. Patients with community-acquired respiratory infections including pneumonia, infective exacerbation of bronchiectasis and active TB are commonly managed in government chest clinics. Thus, we designed a clinical trial to test the null hypothesis that newer fluoroquinolones in the treatment of community-acquired respiratory infection would not mask active pulmonary TB.

METHODS

Patients

We undertook a randomised, open-label controlled trial involving patients with CAP or infective exacerbation of bronchiectasis encountered in multiple government chest clinics in Hong Kong. Adult patients aged ≥18 yrs were eligible for enrolment if they had clinical signs and symptoms of CAP or infective exacerbation of bronchiectasis with compatible findings on the chest radiograph. Symptoms and signs included one or more of the following: cough, sputum, haemoptysis, chest discomfort, shortness of breath, crackles and fever. Patients without symptoms were also eligible in the presence of opacities compatible with consolidations on the chest radiograph. Exclusion criteria were: age <18 yrs; confirmed or suspected pregnancy; positive baseline sputum acid-fast bacilli (AFB) smear or AFB culture, and when either amoxicillin clavulanate or moxifloxacin was inappropriate for the clinical scenario, such as a history of adverse events to amoxicillin clavulanate or moxifloxacin; significant renal impairment; or known congenital or acquired conditions associated with prolonged QTc interval, symptomatic cardiac failure or arrhythmia.

Participants underwent baseline clinical assessment including evaluation by chest radiography, sputum microscopy and bacteriology including AFB culture. Chest radiographs and sputum AFB bacteriology were taken at 6 and 12 months after enrolment and whenever they were considered necessary by the attending physician according to the clinical progress. Further investigations, which included complete blood picture, liver and renal biochemistry, computerised tomography of thorax, and fibreoptic bronchoscopy, could be arranged by the attending physician according to the clinical condition and progress to aid diagnosis or evaluate severity.

Written informed consent was obtained from study participants before enrolment. Approval for conducting the study was obtained from the Ethics Committee of the Dept of Health of Hong Kong Special Administrative Region.

Procedures

A study coordinator allocated eligible patients by random permutated blocks of 20 in equal proportions to one of two arms: moxifloxacin 400 mg once daily for 5 days versus amoxicillin clavulanate 375 mg twice daily plus amoxicillin 750 mg twice daily for 5 days. Baseline dosing schedules were based on published literature about the efficacy of short-course antibiotic treatment of CAP 16. The attending physician was advised not to find out the identity of trial antibiotics unless it was indicated by the clinical condition, such as severe adverse events. The attending physician could extend the duration of study antibiotics, repeat study antibiotics, or prescribe other antibiotics including fluoroquinolones subsequently, according to the clinical progress.

Participants were followed for 1 yr for active pulmonary TB, the primary end-point. Active pulmonary TB was diagnosed when compatible clinical findings coexisted with one or more of the following conditions: isolation of Mycobacterium tuberculosis complex in sputum or bronchial aspirate; compatible histopathological findings in lung tissue; and chest radiographic improvement after empirical TB treatment. The follow-up duration was defined as the time interval between enrolment and onset of TB treatment or, in the absence of TB, the last chest radiograph within 1 yr. A grace period of 1 month after the study period was allowed to ascertain TB status within 1 yr. The TB notification registry was used to help track down all cases of active pulmonary TB.

Besides the primary end-point, the following data were collected: demographics, smoking and drinking history, past health, presenting symptoms, initial chest radiographic findings, initial sputum bacteriology results including AFB culture, clinical and chest radiographic progress within the initial 2 weeks up to 2 months, total number of sputum specimens and chest radiographs taken, antibiotics prescribed throughout the study period including fluoroquinolones other than allocated moxifloxacin, and the final diagnosis.

Statistical analysis

Assuming a Cohen's h value of 0.3 17 for the difference in proportions of active pulmonary TB within 1 yr, a type I error of 5% by two-tailed analysis, and a statistical power of 80%, the sample size per arm would be 175 patients. To allow for 20% loss to follow-up, we aimed at enrolling ∼210 patients per arm. The primary end-point was analysed by modified intention to treat, which meant that all randomised participants would be analysed except for those with positive baseline AFB smear or culture. Besides comparing the proportion of the primary end-point in each treatment arm using statistical tests for categorical data, the Kaplan–Meier survival analysis was used to compare the time to the primary end-point using the log rank test. The Chi-squared test for trend, the log rank test for trend, and the likelihood ratio test statistic obtained from logistic risk models were used to examine whether there would be a dose–response relationship between the diagnosis of active pulmonary TB and moxifloxacin exposure. The Chi-squared test (with or without Yates' correction) or the Fisher's exact test was used to analyse categorical data. Two-sample t-tests or Mann–Whitney U-tests were used for examining continuous variables according to the data distribution pattern. One-way ANOVA or Kruskal–Wallis H tests were used for comparing continuous variables involving more than two groups. Statistical significance was taken as p≤0.05. All analyses were done with SPSS version 10 (SPSS, Inc., Chicago, IL, USA) and R version 2.9.0. This study was registered with www.hkclinicaltrials.com (number HKCTR-185).

RESULTS

From September 2004 to March 2007, a total of 550 patients were assessed for study eligibility. Figure 1⇓ shows the flow of study from assessment of eligibility to analysis. After excluding 123 patients, 427 patients were enrolled and randomly assigned to receive either amoxicillin clavulanate (n = 212) or moxifloxacin (n = 215). Enrolled and excluded subjects were comparable by age (p = 0.09 by two-sample t-test) and by sex (p = 0.75 by Chi-squared test).

Fig. 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1—

Flow chart from enrolment to analysis.

Excluding three patients with positive baseline sputum culture, 424 participants were included in analysis by modified intention to treat. A total of 13 (3.1%) patients developed active pulmonary TB: 10 out of 210 (4.8% (95% confidence interval (CI) 2.6–8.5%)) were given amoxicillin clavulanate, and three out of 214 (1.4% (95% CI 0.5–4.0%)) were given moxifloxacin. The difference was significant both by proportion (p = 0.045) and time-to-event analysis (p = 0.04). The prevalence of culture-proven pulmonary TB in the current cohort was 1.9%.

Tables 1⇓ and 2⇓ show the baseline characteristics and progress of participants. Patients assigned to receive moxifloxacin were largely comparable with those assigned to receive amoxicillin clavulanate with p-values >0.10 by statistical analysis except for previous TB treatment (p = 0.05) and chest pain (p = 0.04), neither of which were significantly associated with active pulmonary TB (p = 0.77 and p = 0.61, respectively).

View this table:
  • View inline
  • View popup
Table 1—

Baseline characteristics and treatment

View this table:
  • View inline
  • View popup
Table 2—

Monitoring and progress

Table 3⇓ compares TB cases by the treatment arm. Patients with active pulmonary TB among the moxifloxacin arm were all given moxifloxacin for 5 days. None of the three TB cases in the moxifloxacin arm was confirmed bacteriologically, whereas eight out of the 10 TB cases given amoxicillin clavulanate were culture-proven; the difference was significant (p = 0.04).

View this table:
  • View inline
  • View popup
Table 3—

Comparing patients with active pulmonary tuberculosis(TB) in the two treatment arms

A total of 379 (89.4%) and 360 (84.9%) patients were followed up for at least 91 days and 181 days, respectively. Loss to follow-up as estimated by expected person-days over a period of 1 yr was ∼16% overall, 18% for participants in the amoxicillin clavulanate arm, and 14% for the moxifloxacin arm. The annual incidence of active pulmonary TB per 100,000 persons (95% CI) was 3,769 (2,111–6,262) overall, 6,072 (3,117–10,773) for participants given amoxicillin clavulanate, and 1,664 (461–4,440) for participants given moxifloxacin. Using TB notification rates of Hong Kong in 2005 as the reference, the expected sex- and age-adjusted incidence rates of active pulmonary TB in the current cohort would be 240 (22–1,108).

Two patients took fluoroquinolones before the diagnosis of culture-proven pulmonary TB. Both were allocated to amoxicillin clavulanate rather than moxifloxacin. One received ciprofloxacin 250 mg twice daily for 2 weeks and 500 mg twice daily for 1 week, ∼14 weeks and 1 week, respectively, before the sputum specimen that isolated M. tuberculosis was collected. The other received ciprofloxacin 250–500 mg twice daily for 2 weeks, and 500 mg twice daily for 1 week, ∼31 weeks and 6 weeks, respectively, before the culture-positive sputum specimen was collected. Drug susceptibility testing showed bacillary susceptibility to ofloxacin in both.

Adverse events occurred in 11 patients allocated to moxifloxacin as follows: hospitalisation for pneumonia and acute exacerbation of chronic obstructive pulmonary disease (n = 2), left pleural effusion (n = 1), and acute respiratory distress syndrome that also occurred within 2 weeks after receiving standard TB treatment (n = 1); dizziness (n = 2); gastrointestinal upset (n = 3); transient twitching of extremities plus slurring of speech (n = 1); and a bitter taste (n = 1). Of these 11 patients, moxifloxacin was suspended in four: three for gastrointestinal upset and one for dizziness. Adverse events occurred in six patients allocated to amoxicillin clavulanate: hospitalisation within 1 month after enrolment for pneumonia (n = 1) and hypoglycaemia (n = 1); vague discomfort (n = 2); diarrhoea (n = 1); and transient chills in extremities (n = 1). Of these six patients, amoxicillin clavulanate was suspended in two patients for ill-defined symptoms (feeling hot and irritable) and generalised vague discomfort.

Post hoc analysis of dose–response relationship

The significant negative association between active pulmonary TB and exposure to moxifloxacin prompted a closer examination for any dose–response relationship among three subgroups of participants with different moxifloxacin exposure. The proportion with active pulmonary TB decreased significantly from 4.8% among participants given amoxicillin clavulanate (n = 210) to 2.4% and 0%, respectively, among those given moxifloxacin for 5–7 days (n = 127) and 10–15 days within 4 weeks (n = 87; p = 0.03). The log rank test for trend also showed a significant difference between the three subgroups (p = 0.02).

Online supplementary tables E1 and E2 compare baseline characteristics and progress of participants allocated to amoxicillin clavulanate (n = 210), moxifloxacin for 5–7 days (n = 127) and moxifloxacin for 10–15 days within 4 weeks (n = 87). The three groups were largely comparable, with p-values >0.10 by statistical analysis except for the following factors: previous TB treatment (p = 0.04), history of bronchiectasis (p = 0.07), chest pain (p = 0.09), fever (p = 0.01), symptomatic response within the initial 2 months (p = 0.01), and chest radiographic progress within the initial 2 months (p = 0.05). None of these factors were significantly associated with active pulmonary TB except for the last two (p = 0.001 and p<0.001, respectively).

To further examine the dose–response relationship between moxifloxacin exposure and active pulmonary TB, we tested the null hypothesis that the exposure effect of moxifloxacin was linear by comparing a logistic risk model that assumed a linear effect and a more general model in which the exposure effect was assumed to be non-linear. Ten covariates were included in the model: allocated antibiotics (amoxicillin clavulanate, moxifloxacin for 5–7 days, and moxifloxacin for 10–15 days), fluoroquinolones other than allocated moxifloxacin, sex, age, history of drinking, past TB treatment, history of bronchiectasis, presence or absence of symptoms on presentation, and cavitation and extent of disease on initial chest radiographs. Significant collinearity was excluded. The null hypothesis could not be rejected (likelihood ratio test statistic = 1.40; p = 0.24). Findings reaffirmed a dose–response relationship between moxifloxacin exposure and diagnosis of active pulmonary TB. Table 4⇓ shows a logistic risk model that assumes a linear effect for moxifloxacin exposure. The adjusted odds ratio (95% CI) of active pulmonary TB after moxifloxacin exposure up to predominantly 10 days over 4 weeks was 0.3 (0.1–0.9), or 0.9 (0.3–3.0) after exposure for 1 day. Logistic risk models have been used instead of Cox models because coefficients failed to converge during Cox regression analysis.

View this table:
  • View inline
  • View popup
Table 4—

A logistic risk model that assumes a linear effect for moxifloxacin exposure

DISCUSSION

The overall annual incidence rate of active pulmonary TB in the current cohort was ∼16 times that of the sex- and age-adjusted TB notification rates of Hong Kong in 2005. The observed prevalence (1.9%) of culture-proven active pulmonary TB in the current cohort was comparable with that observed in another local cohort hospitalised for CAP 18. Patients given amoxicillin clavulanate had a significantly higher proportion of active pulmonary TB within 1 yr than those who were given moxifloxacin (p = 0.045). Post hoc analysis showed a significant decrease in the proportion with active pulmonary TB from 4.8% among participants given amoxicillin clavulanate to 2.4% and 0% among those given moxifloxacin for predominantly 5 days and predominantly 10 days within 4 weeks, respectively (p = 0.03 by Chi-squared test for trend). The linear effect was reaffirmed in regression models. A logistic risk model with a linear effect for moxifloxacin exposure showed that the adjusted odds ratio (95% CI) of active pulmonary TB after moxifloxacin exposure up to predominantly 10 days over 4 weeks was 0.3 (0.1–0.9), or 0.9 (0.3–3.0) after exposure for 1 day.

With less error due to selection bias and confounding in comparison with retrospective studies, the current randomised controlled trial has put the risk of using fluoroquinolones for treating community-acquired respiratory infection into a better perspective. Dooley et al. 14 showed that initial empirical therapy with fluoroquinolones was associated with a delay in TB treatment (21 days versus 5 days). In a retrospective analysis involving 548 TB patients, Wang et al. 19 demonstrated that exposure to fluoroquinolones delayed TB treatment and was associated with poor prognosis. Our findings show that newer fluoroquinolones, such as moxifloxacin, appear to mask TB in proportion to the duration of exposure in TB-endemic areas.

Allowing use of nonstudy antibiotics and flexibility in the dosing duration of study antibiotics and frequency of chest radiographic examination and sputum AFB bacteriology probably rendered the current trial more like a real-life situation. Despite the lack of a double-blind placebo-controlled design, randomisation was probably adequate, as shown by tables 1⇑ and 2⇑. It might be argued that in the absence of blinding, the attending physician might be prone to start empirical TB treatment in the moxifloxacin arm. If this were the case, more patients in the moxifloxacin arm would have received TB treatment. There were in fact more TB cases among patients allocated to receive amoxicillin clavulanate.

Although a dose–response relationship between moxifloxacin and masking of TB could be reaffirmed in the current study through regression models, the linear effect might have been better shown without regression analysis had the study design included two moxifloxacin arms with different treatment durations allocated by randomisation. Symptomatic response and chest radiographic progress within the initial 2 months were deliberately excluded from regression analysis despite their significant association with both moxifloxacin exposure and active pulmonary TB; inclusion would have been inappropriate as moxifloxacin probably masks TB through improvement in symptoms or chest radiography 20.

The small number of TB cases made it difficult for the current trial to address the association between newer fluoroquinolones and culture-negative pulmonary TB. Although a retrospective study showed no significant association between fluoroquinolone exposure and an increased risk of culture-negative TB 21, further studies are warranted to examine whether prolonged or multiple courses of newer fluoroquinolones may reduce sputum culture yield of active pulmonary TB.

Another concern about treating community-acquired chest infection with fluoroquinolones is the emergence of fluoroquinolone-resistant TB. The small number of study participants with exposure to fluoroquinolones before a culture-positive sputum specimen was collected made it difficult for the current trial to address this issue. However, a number of studies have reported a low risk of fluoroquinolone-resistant TB among patients exposed to fluoroquinolones prior to the diagnosis of TB 22–24. Huang et al. 25 found that resistance to fluoroquinolones was probably due to use of fluoroquinolones among patients with multidrug-resistant TB rather than the general community. It has also been suggested that newer fluoroquinolones with better pharmacokinetic and pharmacodynamic properties help reduce the risk of developing drug resistance in M. tuberculosis 26. Some preliminary evidence in that direction regarding high-dose moxifloxacin and levofloxacin were indeed obtained 27, 28. However, the safety and tolerance of these higher dosages require further exploration 27. Current data also favour shortening the duration of antibiotic treatment at an optimal dosage to reduce the risk of acquired resistance 24, 29. In corroboration with recent findings of an association between fluoroquinolone-resistant TB and prolonged or multiple courses of fluoroquinolones 22, 30, the current study would caution against fluoroquinolone use in excess of 5 days or multiple courses in TB-endemic areas to reduce the risk of masking active TB alongside that of developing fluoroquinolone-resistant TB.

The impact of HIV infection on the findings of our clinical trial could not be examined because the prevalence of HIV in Hong Kong was <1% 15. As the clinical and radiographic presentation of pulmonary TB in HIV-infected subjects become atypical with immunosuppression, whether findings of the current trial may also apply to areas that are endemic for both TB and HIV is uncertain.

In conclusion, newer fluoroquinolones, such as moxifloxacin, appear to mask active pulmonary TB in proportion to the duration of exposure in TB-endemic areas.

Clinical trials

This study was registered with www.hkclinicaltrials.com (number HKCTR-185).

Statement of interest

None declared.

Acknowledgments

The authors would like to extend their gratitude to all nurses of the Tuberculosis and Chest Service of the Dept of Health, Hong Kong Special Administrative Region, for their invaluable help. Special thanks go to L. Ku for coordinating the study, and I. Mak and B. Wong for data entry (all Tuberculosis and Chest Service of the Dept of Health, Hong Kong Special Administrative Region).

Footnotes

  • This article has supplementary material accessible from www.erj.ersjournals.com

  • Received July 3, 2009.
  • Accepted August 20, 2009.
  • © ERS Journals Ltd

References

  1. ↵
    Lode H, Garau J. Improving care for patients with respiratory tract infections. J Chemother 2002;14: Suppl. 2 22–28.
    OpenUrlPubMed
  2. Tillotson GS. Role of gemifloxacin in community-acquired pneumonia. Expert Rev Anti Infect Ther 2008;6:405–418.
    OpenUrlCrossRefPubMedWeb of Science
  3. Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother 2008;9:1755–1772.
    OpenUrlCrossRefPubMedWeb of Science
  4. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008;179:1269–1277.
    OpenUrlAbstract/FREE Full Text
  5. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185–195.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135–143.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44: Suppl. 2 S27–S72.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744–751.
    OpenUrlCrossRefPubMedWeb of Science
  9. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003;124:1476–1481.
    OpenUrlCrossRefPubMedWeb of Science
  10. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103–1109.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318–326.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128–138.
    OpenUrlPubMedWeb of Science
  13. ↵
    Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183–1189.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002;34:1607–1612.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Tuberculosis and Chest Service of the Dept of Health. Annual Report 2007. The Government of Hong Kong SAR
  16. ↵
    Mandell LA, File TMJ. Short-course treatment of community-acquired pneumonia. Clin Infect Dis 2003;37:761–763.
    OpenUrlFREE Full Text
  17. ↵
    Cohen J. Statistical Power Analysis for the Behavioral Sciences. Rev. Edn. New York, Academic Press, 1977
  18. ↵
    Ko FWS, Lam RKY, Li TST, et al. Sputum bacteriology in patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease and concomitant pneumonia in Hong Kong. Intern Med J 2005;35:661–667.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    Wang J, Hsueh P, Jan I, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006;61:903–908.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Rothman KJ. Epidemiology: An Introduction. New York, Oxford University Press, Inc., 2002
  21. ↵
    Gaba PD, Haley C, Griffin MR, et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007;167:2317–2322.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009;48:1354–1360.
    OpenUrlAbstract/FREE Full Text
  23. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432–442.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003;37:1448–1452.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Huang T, Kunin CM, Shin-Jung Lee S, et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995–2003. J Antimicrob Chemother 2005;56:1058–1062.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007;44:681–688.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004;190:1642–1651.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:<1?show=[to]?>605–612.
    OpenUrl
  29. ↵
    Low DE. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis 2009;48:1361–1363.
    OpenUrlFREE Full Text
  30. ↵
    Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in M. tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365–370.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 35 Issue 3 Table of Contents
European Respiratory Journal: 35 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?
K. C. Chang, C. C. Leung, W. W. Yew, T. Y. Lau, W. M. Leung, C. M. Tam, H. C. Lam, P. S. Tse, M. Y. Wong, S. N. Lee, K. I. Wat, Y. H. Ma
European Respiratory Journal Mar 2010, 35 (3) 606-613; DOI: 10.1183/09031936.00104209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?
K. C. Chang, C. C. Leung, W. W. Yew, T. Y. Lau, W. M. Leung, C. M. Tam, H. C. Lam, P. S. Tse, M. Y. Wong, S. N. Lee, K. I. Wat, Y. H. Ma
European Respiratory Journal Mar 2010, 35 (3) 606-613; DOI: 10.1183/09031936.00104209
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Clinical trials
    • Statement of interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection
  • Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors
Show more Original Articles: Respiratory infections and tuberculosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society